Ways to increase the effectiveness of hypertension correction during antitumor therapy with the use of VEGF inhibitors

Abstract

In recent years, cardioncology has rapidly become responsible for comprehensive decision-making appropriate cancer patients receiving cardiotoxic cancer therapy. Currently, the implementation of a multidisciplinary approach in the correction of adverse events using various drug antitumor therapy regimens is becoming increasingly relevant. In particular, given the widespread use of vascular-endothelial growth factor inhibitors, both at the heart of complex schemes and in mono-supportive modes. It is important to timely identify and correct such a clinically significant adverse event as an increase in blood pressure at the time of administration and in the early follow-up period. Adherence to standard drug regimens for hypertension, which usually provide satisfactory blood pressure control between cycles of administration of vascular-endothelial growth factor inhibitors, in a number of patients did not allow the same effective retention of blood pressure in the planned intervals with the administration of bevacizumab. The intensification of drug therapy for hypertension, both at the pre-infusion stage and at the time of an increase in blood pressure, was of a multidirectional nature. Search and summarize information on the availability and development of physiotherapeutic treatment methods for the correction of hypertension during antitumor therapy in cancer patients using vascular-endothelial growth factor inhibitors. 35 literature sources were analyzed. There are no data on the development of physiotherapeutic methods for the treatment of bevacizumab-induced hypertension. Domestic sources ― 25 articles. Foreign sources ― 10 articles. An analysis of the literature concluded that there is a lack of research on the development of physiotherapeutic methods for the treatment of bevacizumab-induced hypertension. In order to reduce the cardiotoxicity of humanized recombined monoclonal antibodies, maintain the dose interval period, improve survival and eliminate the need for dose adjustment of antihypertensive drugs, it is proposed to consider the use of preformed physical factors in the treatment of bevacizumab-induced hypertension.